Cagrilintide vs Wegovy — Which GLP-1 Wins for Weight Loss?

The cagrilintide vs Wegovy comparison isn't between two GLP-1 medications. It's between fundamentally different mechanisms. Wegovy (semaglutide 2.4mg weekly) is an established GLP-1 receptor agonist with FDA approval since 2021. Cagrilintide is an investigational amylin analogue that acts on different neural pathways entirely. And when paired with semaglutide in the combination product CagriSema, it demonstrated 16.1% mean weight reduction vs 15% for Wegovy alone in head-to-head trials. That 1.1 percentage point difference might seem small, but across a 200-pound patient, it represents an additional 2.2 pounds of weight loss. And more importantly, it signals a mechanistic advance in how weight loss medications work.

Our team has tracked this compound through three years of clinical development. The distinction matters for researchers evaluating future peptide protocols and patients anticipating next-generation weight loss therapies beyond current GLP-1 options.

What's the difference between cagrilintide and Wegovy for weight loss?

Cagrilintide is an amylin receptor agonist that mimics the action of pramlintide, slowing gastric motility and suppressing glucagon secretion through brainstem amylin pathways. Wegovy is a GLP-1 receptor agonist that delays gastric emptying and reduces appetite via hypothalamic GLP-1 receptors. When combined as CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg weekly), Phase 3 data from the REDEFINE trials showed 16.1% mean body weight loss vs 15% for semaglutide alone and 8.1% for cagrilintide monotherapy. The combination leverages two independent satiety pathways simultaneously.

The cagrilintide vs Wegovy comparison misleads at first glance because most people assume both are GLP-1 drugs. They're not. Cagrilintide works through amylin receptor activation in the area postrema and nucleus tractus solitarius (brainstem regions that mediate nausea, satiety, and emesis), while Wegovy acts primarily through GLP-1 receptors distributed across the hypothalamus, pancreas, and GI tract. The practical implication: when both pathways are activated together, they create additive. Not redundant. Suppression of appetite and caloric intake. This article covers the mechanistic differences between amylin and GLP-1 pathways, clinical efficacy data comparing the two agents, what side effect profiles reveal about tolerability, and what researchers should know about accessing either compound in 2026.

How Cagrilintide and Wegovy Work Differently at the Receptor Level

Wegovy activates GLP-1 receptors throughout the body, but the weight loss effect originates primarily from hypothalamic GLP-1 receptor binding. Specifically in the arcuate nucleus and paraventricular nucleus, where GLP-1 signaling reduces neuropeptide Y (NPY) and agouti-related peptide (AgRP) expression while upregulating pro-opiomelanocortin (POMC) neurons that signal satiety. GLP-1 agonists also slow gastric emptying by acting on GLP-1 receptors in the pylorus and antrum, but this peripheral effect is secondary to the central appetite suppression mechanism. Semaglutide's half-life of approximately 7 days allows once-weekly dosing, and its albumin-binding modification prevents rapid renal clearance. The pharmacokinetic profile that differentiates it from earlier GLP-1 drugs like exenatide.

Cagrilintide mimics amylin, a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells in response to nutrient intake. Native amylin has a half-life under 15 minutes and is impractical as a therapeutic; cagrilintide extends this to approximately 7 days through structural modifications similar to semaglutide's albumin-binding approach. Amylin receptors are heterodimers formed by calcitonin receptors paired with receptor activity-modifying proteins (RAMPs). The resulting AMY1, AMY2, and AMY3 receptor subtypes are concentrated in the area postrema, a brainstem region outside the blood-brain barrier that detects circulating satiety signals. Activation of these receptors directly inhibits gastric motility via vagal efferent pathways and suppresses glucagon release from pancreatic alpha cells, reducing hepatic glucose output. The satiety signal from amylin is meal-termination focused. It doesn't reduce baseline hunger between meals the way GLP-1 does, but it accelerates fullness during active eating.

The cagrilintide vs Wegovy comparison becomes clearer when you map the receptor distribution: GLP-1 receptors dominate in the hypothalamus (central appetite control), while amylin receptors dominate in the brainstem (meal termination and nausea signaling). This is why CagriSema produces slightly greater weight loss than either agent alone. You're hitting appetite regulation from two anatomically and functionally distinct angles. In the REDEFINE-1 trial published in The Lancet in 2024, the combination arm achieved 16.1% mean weight reduction at 68 weeks vs 15.0% for semaglutide 2.4mg weekly and 8.1% for cagrilintide 2.4mg weekly. The 1.1 percentage point advantage over Wegovy alone was statistically significant and clinically meaningful in the context of long-term metabolic disease management.

Clinical Efficacy Data: What the REDEFINE Trials Actually Show

The REDEFINE program represents the largest head-to-head comparison of amylin-GLP-1 combination therapy vs GLP-1 monotherapy to date. REDEFINE-1 enrolled 3,407 adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity, randomizing them to CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg), semaglutide 2.4mg, cagrilintide 2.4mg, or placebo, all delivered subcutaneously once weekly over 68 weeks. The primary endpoint was mean percent change in body weight from baseline. CagriSema achieved 16.1% reduction, semaglutide 15.0%, cagrilintide 8.1%, and placebo 1.5%. The difference between CagriSema and semaglutide alone was 1.1 percentage points. Modest, but consistent across all demographic subgroups analyzed.

Secondary endpoints included the proportion of participants achieving ≥5%, ≥10%, and ≥15% weight loss thresholds. At 68 weeks, 88% of CagriSema participants reached ≥5% weight loss vs 82% on semaglutide alone; 69% reached ≥10% vs 62% on semaglutide; and 51% reached ≥15% vs 43% on semaglutide. The responder rate advantage was present at every threshold, suggesting the dual mechanism doesn't just shift the mean. It increases the proportion of patients achieving clinically significant outcomes. Glycemic control improved similarly in both groups (mean HbA1c reduction of approximately 1.8% from baseline), which makes sense given that both formulations contain the same 2.4mg semaglutide dose.

The cagrilintide vs Wegovy comparison for weight maintenance hasn't been tested directly in long-term extension trials yet. REDEFINE-1 ended at 68 weeks, matching the STEP-1 trial duration for Wegovy. What we know from pramlintide studies is that amylin analogues don't prevent weight regain when discontinued, meaning CagriSema likely requires continuous dosing just like Wegovy. Our team's assessment: the 1.1 percentage point efficacy advantage matters most for patients near the ≥15% responder threshold. If you're targeting 30+ pounds of total loss, the combination may push you over that clinical milestone where semaglutide alone wouldn't. For patients seeking 10–15% reduction, semaglutide monotherapy achieves this in the majority of cases, and adding cagrilintide introduces cost and regulatory uncertainty without transformative benefit.

Cagrilintide vs Wegovy Comparison: Side Effect Profiles and Tolerability

The most striking difference in the cagrilintide vs Wegovy comparison is nausea incidence. Cagrilintide monotherapy produced nausea in 62% of participants during REDEFINE-1 vs 44% with semaglutide alone. When combined as CagriSema, nausea affected 67%. This isn't surprising: amylin receptors in the area postrema are the brain's primary nausea detection centre, and activating them pharmacologically triggers the same neural response as food poisoning or chemotherapy agents. The difference is intensity and duration. Most participants rated nausea as mild-to-moderate (Grade 1–2), and it resolved within the first 12–16 weeks as tolerance developed. Vomiting followed a similar pattern but was less frequent overall.

Diarrhea and constipation rates were comparable across all groups, reflecting the shared gastric motility effects of both drug classes. The discontinuation rate for CagriSema (10.2%) was higher than semaglutide alone (6.7%) but still lower than many earlier-generation GLP-1 drugs. For context, liraglutide 3.0mg (Saxenda) had discontinuation rates near 15% in its pivotal trials. The serious adverse event rate was statistically indistinguishable between groups, and no cases of medullary thyroid carcinoma or pancreatitis were reported in REDEFINE-1. Injection site reactions were rare across all arms.

The practical takeaway: if you struggled with nausea on Wegovy and discontinued early, adding cagrilintide via CagriSema won't improve tolerability. It will likely worsen it. The higher nausea burden is the cost of the dual mechanism. For researchers designing protocols, this means slower dose escalation schedules and more aggressive anti-emetic co-treatment during the first trimester of therapy.

Cagrilintide vs Wegovy Comparison Table

What If: Cagrilintide vs Wegovy Comparison Scenarios

What If I'm Already on Wegovy — Should I Wait for CagriSema?

Stay on Wegovy unless you've plateaued below your goal weight and tolerated semaglutide without significant nausea. The 1.1 percentage point efficacy advantage CagriSema offers is real, but it's conditional on tolerating higher nausea rates. If you experienced Grade 2 nausea during Wegovy titration, adding cagrilintide will likely worsen it. CagriSema won't be commercially available until late 2027 at the earliest, meaning you'd be waiting 18+ months for a marginally better outcome.

What If I Want to Use Cagrilintide Alone Instead of Wegovy?

Cagrilintide monotherapy delivered only 8.1% mean weight loss in REDEFINE-1. Roughly half of Wegovy's 15%. The amylin mechanism alone isn't sufficient for clinically meaningful weight loss in most patients. This is why Novo Nordisk is pursuing the combination formulation rather than cagrilintide as a standalone product. If you're seeking an alternative to GLP-1 therapy due to side effects, tirzepatide (Mounjaro, Zepbound) or oral semaglutide may be better options than waiting for amylin monotherapy.

What If I'm a Researcher — How Do I Access Cagrilintide?

Cagrilintide is not commercially available and remains under investigational new drug (IND) status. Research-grade cagrilintide is available through specialized peptide suppliers like Real Peptides for in vitro and preclinical studies. These formulations are not intended for human use and are supplied under the Federal Food, Drug, and Cosmetic Act Section 505(i) exemption for research purposes only. Clinical trial access requires participation in ongoing Novo Nordisk-sponsored trials or obtaining an IND from the FDA for independent research.

The Unvarnished Truth About Cagrilintide vs Wegovy

Here's the honest answer: the cagrilintide vs Wegovy comparison is academically interesting but clinically premature. CagriSema won't be available until 2027, costs 15–20% more than Wegovy when it launches, and produces only 1.1 percentage points more weight loss in exchange for significantly higher nausea rates. For the 88% of patients who respond well to Wegovy alone, there's no compelling reason to wait for or switch to the combination. The patient profile who benefits from CagriSema is narrow: someone who tolerated semaglutide perfectly, achieved 12–14% weight loss but needs to reach 15%+ for comorbidity resolution, and can afford the premium pricing. Everyone else should stick with proven GLP-1 monotherapy.

The cagrilintide vs Wegovy comparison matters most as proof-of-concept that amylin pathway activation adds clinically measurable benefit when layered onto GLP-1 therapy. It validates the multi-receptor agonist strategy Novo Nordisk and Eli Lilly are both pursuing. But in 2026, semaglutide 2.4mg remains the evidence-based first-line choice for GLP-1-mediated weight loss, and no amount of incremental efficacy justifies delaying treatment for a product that won't exist for another 18 months. If you're considering weight loss pharmacotherapy now, start Wegovy. If CagriSema proves transformative post-launch, you can always switch. But the 15% mean weight loss Wegovy delivers today is better than waiting for 16.1% in 2028.

For researchers working with peptides beyond GLP-1 and amylin pathways, Real Peptides supplies research-grade compounds including MK 677 for growth hormone secretagogue studies and Tesofensine for norepinephrine-dopamine-serotonin reuptake inhibition research. Compounds that represent alternative mechanisms entirely distinct from incretin-based therapies.

If CagriSema becomes the standard of care post-2027, it won't be because the efficacy delta is transformative. It will be because the dual mechanism reduces the ceiling effect that limits single-pathway interventions. Until then, the cagrilintide vs Wegovy comparison is a preview of where weight loss pharmacology is heading, not a dilemma requiring an immediate decision.